Association Between Mineralocorticoid Receptor Antagonist Use and Outcome in Myocardial Infarction Patients With Heart Failure

Association Between Mineralocorticoid Receptor Antagonist Use and Outcome in Myocardial Infarction Patients With Heart Failure

Bibliographic Details
Format:	Article
Language:	English
Published:	Wiley 2019-02-01
Series:	Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Online Access:	https://www.ahajournals.org/doi/10.1161/JAHA.117.004268

Similar Items

Heart failure: the role for mineralocorticoid receptor antagonists
by: Bertram Pitt
Published: (2014-05-01)

Clinical application of mineralocorticoid receptor antagonists in chronic heart failure
by: MG Bubnova
Published: (2014-12-01)

Hyperkalaemia as a cause of undertreatment with mineralocorticoid receptor antagonists in heart failure
by: Josefin Henrysson, et al.
Published: (2023-02-01)

Importance of the time of initiation of mineralocorticoid receptor antagonists on risk of mortality in patients with heart failure
by: Rosario Rossi, et al.
Published: (2015-03-01)

Effects of Mineralocorticoid Receptor Antagonists in Early-Stage Heart Failure With Preserved Ejection Fraction
by: Kazuki Kagami, MD, et al.
Published: (2023-05-01)

In the wake of the latest clinical guidelines - mineralocorticoid receptor antagonists in the treatment of chronic heart failure
by: I. V. Zhirov, et al.
Published: (2015-12-01)

The non-steroidal mineralocorticoid receptor antagonist finerenone and heart failure with preserved ejection fraction
by: Ulrich Kintscher, et al.
Published: (2023-06-01)

Mineralocorticoid Receptor Antagonists Mitigate Mitral Regurgitation-Induced Myocardial Dysfunction
by: Wei-Ting Chang, et al.
Published: (2022-09-01)

Changes of myocardial fibrosis markers with the use of beta-blockers and mineralocorticoid receptor antagonists in patients with heart failure with mid-range ejection fraction of ischemic origin
by: O. A. Osipova, et al.
Published: (2021-11-01)

Serum potassium level and mineralocorticoid receptor antagonist dose in a large cohort of chronic heart failure patients
by: Pascal R. D. Clephas, et al.
Published: (2023-04-01)

Incremental value of mineralocorticoid receptor antagonists in patients with heart failure with reduced ejection fraction treated with sacubitril/valsartan
by: Burkert Pieske, et al.
Published: (2022-12-01)

Mineralocorticoid receptor antagonists for chronic heart failure: a meta-analysis focusing on the number needed to treat
by: Chang Geng, et al.
Published: (2023-11-01)

Mineralocorticoid Receptor Antagonists—Use in Chronic Kidney Disease
by: Wiktoria Baran, et al.
Published: (2021-09-01)

The Effect of Mineralocorticoid Receptor 3 Antagonists on Anti-Inflammatory and Anti-Fatty Acid Transport Profile in Patients with Heart Failure
by: Xiaoran Fu, et al.
Published: (2022-04-01)

Correction: Incremental value of mineralocorticoid receptor antagonists in patients with heart failure with reduced ejection fraction treated with sacubitril/valsartan
Published: (2023-03-01)

Mineralocorticoid Receptor Antagonists in Diabetic Kidney Disease
by: Nina Vodošek Hojs, et al.
Published: (2021-06-01)

Ongoing clinical trials with angiotensin II receptor antagonists in chronic heart failure and myocardial infarction
by: John McMurray, et al.
Published: (2000-06-01)

THE USE OF MINERALOCORTICOID RECEPTOR ANTAGONISTS IN THE PRE VENTION OF ATRIAL FIBRILLATION
by: N. T. Vatutin, et al.
Published: (2019-07-01)

Nonsteroidal Mineralocorticoid Receptor Antagonist (Finerenone) in Cardiorenal Disease
by: Monarch Shah, et al.
Published: (2023-09-01)

Mineralocorticoid receptor antagonists: emerging roles in cardiovascular medicine
by: Funder JW
Published: (2013-10-01)

Benefits of the Non-Steroidal Mineralocorticoid Receptor Antagonist Finerenone in Metabolic Syndrome-Related Heart Failure with Preserved Ejection Fraction
by: Ixchel Lima-Posada, et al.
Published: (2023-01-01)

A SELECTIVE ANTAGONIST OF MINERALOCORTICOID RECEPTOR EPLERENONE IN CARDIOLOGY PRACTICE
by: B. B. Gegenava, et al.
Published: (2015-09-01)

Paradigm shift on the role of mineralocorticoid receptor antagonists in hypertension therapy
by: S. R. Gilyarevsky, et al.
Published: (2023-10-01)

Novel 1,4-Dihydropyridine Derivatives as Mineralocorticoid Receptor Antagonists
by: Felipe Luis Pérez-Gordillo, et al.
Published: (2023-01-01)

Mineralocorticoid receptor antagonists: new extended roles in cardio- and nephroprotection
by: A. M. Esayan, et al.
Published: (2018-04-01)

A SELECTIVE ANTAGONIST OF MINERALOCORTICOID RECEPTOR EPLERENONE IN CARDIOLOGY PRACTICE
by: B. B. Gegenava, et al.
Published: (2015-09-01)

Negative Prognostic Impact of Mineralocorticoid Receptor Antagonist in Elderly Patients Receiving TAVR
by: Teruhiko Imamura, et al.
Published: (2023-05-01)

Cost Effectiveness of Sodium-Glucose Cotransporter 2 Inhibitors Compared with Mineralocorticoid Receptor Antagonists among Patients with Heart Failure and a Reduced Ejection Fraction
by: Jingchaun Guo, et al.
Published: (2023-05-01)

Potential Impact of Non-Steroidal Mineralocorticoid Receptor Antagonists in Cardiovascular Disease
by: Asadur Rahman, et al.
Published: (2023-01-01)

Network meta-analysis of mineralocorticoid receptor antagonists for diabetic kidney disease
by: Yichuan Wu, et al.
Published: (2022-09-01)

Renal Protection of Mineralocorticoid Receptor Antagonist, Finerenone, in Diabetic Kidney Disease
by: Dong-Lim Kim, et al.
Published: (2023-02-01)

Association between Mineralocorticoid Receptor Antagonist and Mortality in SARS-CoV-2 Patients: A Systematic Review and Meta-Analysis
by: Jean Kim, et al.
Published: (2022-03-01)

Mineralocorticoid Receptor Antagonists Eplerenone and Spironolactone Modify Adrenal Cortex Morphology and Physiology
by: Sofia S. Pereira, et al.
Published: (2021-04-01)

Spontaneous Remission of Primary Aldosteronism with Mineralocorticoid Receptor Antagonist Therapy: A Review
by: Xurong Mai, et al.
Published: (2022-11-01)

MINERALOCORTICOID RECEPTOR ANTAGONISTS THERAPY IN RESISTANT HYPERTENSION: TIME TO IMPLEMENT NEW GUIDELINES?
by: Giuseppe eMaiolino, et al.
Published: (2015-02-01)

Timing of heart failure development and clinical outcomes in patients with acute myocardial infarction
by: Hyung Yoon Kim, et al.
Published: (2023-06-01)

Use of Valsartan in Post-Myocardial Infarction and Heart Failure Patients
by: Peter P Liu, et al.
Published: (2006-03-01)

Use of Valsartan in Post-Myocardial Infarction and Heart Failure Patients
by: Peter P Liu, et al.
Published: (2006-03-01)

Evolution of Mineralocorticoid Receptor Antagonists in the Treatment of Chronic Kidney Disease Associated with Type 2 Diabetes Mellitus
by: Jay B. Wish, MD, et al.
Published: (2022-12-01)

Heart failure and anemia in patients with acute myocardial infarction
by: T. Yu. Kalyuta, et al.
Published: (2005-02-01)